Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035639041> ?p ?o ?g. }
- W2035639041 endingPage "454" @default.
- W2035639041 startingPage "449" @default.
- W2035639041 abstract "Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNα, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chronic phase. Eighteen patients were treated with ATRA at a dose of 80 mg/m2/day (p.o.), divided into two equal doses after meals, for 7 consecutive days every other week for a maximum of 12 courses (1 course = 1 week on and 1 week off). Pharmacokinetic profiles of ATRA were evaluated during intermittent therapy on days 1 and 7 of course 1; on day 1 of course 2; on day 1 of course 6. Out of the 18 patients treated with ATRA, 11 (61%) went off study before the sixth course of treatment because of progressive hyperleukocytosis (seven cases), or thrombocytosis (one case), or refusal (three cases). Seven (39%) patients completed the first six courses (12 weeks) of treatment with ATRA and two of them (11%) maintained a white blood cell (WBC) <10 × 109/l which was induced by the pretreatment with hydroxyurea. One patient completed the 12th course of ATRA maintaining WBC <10 × 109/l, platelets <500 × 109/l and spleen not palpable. The treatment with ATRA was well tolerated and only one patient discontinued the therapy because of non-hematological side-effects. The area under the concentration-time curve (AUC) decreased significantly (P < 0.001) during the first week of therapy. by adopting an intermittent dosing regimen, 1 week on/ 1 week off (1 course), at the start of courses 2 and 6, we obtained the atra aucs equivalent to the ones achieved on day 1 of course 1. in conclusion, our results showed that atra alone appeared to be unable to control the wbc expansion in the cml patients in chronic phase. moreover, it did not induce any remarkable cytoreductive effects on the platelet count and on the hemoglobin level. the major interest of atra would be in combination with other therapies. if atra was given in combination with ifnα or other agents, dose reduction of these would not be planned. on the basis of the pharmacokinetic profile, atra should be administered intermittently rather than continuously." @default.
- W2035639041 created "2016-06-24" @default.
- W2035639041 creator A5003619706 @default.
- W2035639041 creator A5006410643 @default.
- W2035639041 creator A5012105863 @default.
- W2035639041 creator A5017814449 @default.
- W2035639041 creator A5028913158 @default.
- W2035639041 creator A5029591572 @default.
- W2035639041 creator A5037637576 @default.
- W2035639041 creator A5044885843 @default.
- W2035639041 creator A5046494145 @default.
- W2035639041 creator A5049158191 @default.
- W2035639041 creator A5051100697 @default.
- W2035639041 creator A5060796171 @default.
- W2035639041 creator A5063734987 @default.
- W2035639041 creator A5066925260 @default.
- W2035639041 creator A5068687462 @default.
- W2035639041 creator A5081294616 @default.
- W2035639041 date "1998-04-01" @default.
- W2035639041 modified "2023-10-15" @default.
- W2035639041 title "All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase" @default.
- W2035639041 cites W1521909328 @default.
- W2035639041 cites W1585236989 @default.
- W2035639041 cites W17800351 @default.
- W2035639041 cites W1838818166 @default.
- W2035639041 cites W1974581900 @default.
- W2035639041 cites W1976861058 @default.
- W2035639041 cites W1977627834 @default.
- W2035639041 cites W2021420193 @default.
- W2035639041 cites W2086161707 @default.
- W2035639041 cites W2090599426 @default.
- W2035639041 cites W2091906464 @default.
- W2035639041 cites W2135119731 @default.
- W2035639041 cites W2185703542 @default.
- W2035639041 cites W2221833316 @default.
- W2035639041 cites W2245941149 @default.
- W2035639041 cites W2269450671 @default.
- W2035639041 cites W2276843828 @default.
- W2035639041 cites W2327237185 @default.
- W2035639041 cites W2398701509 @default.
- W2035639041 cites W2407345634 @default.
- W2035639041 cites W2409419195 @default.
- W2035639041 cites W2410016017 @default.
- W2035639041 cites W2422106878 @default.
- W2035639041 cites W2424804778 @default.
- W2035639041 cites W2438710758 @default.
- W2035639041 doi "https://doi.org/10.1038/sj.leu.2400988" @default.
- W2035639041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9557600" @default.
- W2035639041 hasPublicationYear "1998" @default.
- W2035639041 type Work @default.
- W2035639041 sameAs 2035639041 @default.
- W2035639041 citedByCount "14" @default.
- W2035639041 countsByYear W20356390412017 @default.
- W2035639041 countsByYear W20356390412018 @default.
- W2035639041 countsByYear W20356390412020 @default.
- W2035639041 crossrefType "journal-article" @default.
- W2035639041 hasAuthorship W2035639041A5003619706 @default.
- W2035639041 hasAuthorship W2035639041A5006410643 @default.
- W2035639041 hasAuthorship W2035639041A5012105863 @default.
- W2035639041 hasAuthorship W2035639041A5017814449 @default.
- W2035639041 hasAuthorship W2035639041A5028913158 @default.
- W2035639041 hasAuthorship W2035639041A5029591572 @default.
- W2035639041 hasAuthorship W2035639041A5037637576 @default.
- W2035639041 hasAuthorship W2035639041A5044885843 @default.
- W2035639041 hasAuthorship W2035639041A5046494145 @default.
- W2035639041 hasAuthorship W2035639041A5049158191 @default.
- W2035639041 hasAuthorship W2035639041A5051100697 @default.
- W2035639041 hasAuthorship W2035639041A5060796171 @default.
- W2035639041 hasAuthorship W2035639041A5063734987 @default.
- W2035639041 hasAuthorship W2035639041A5066925260 @default.
- W2035639041 hasAuthorship W2035639041A5068687462 @default.
- W2035639041 hasAuthorship W2035639041A5081294616 @default.
- W2035639041 hasBestOaLocation W20356390411 @default.
- W2035639041 hasConcept C104317684 @default.
- W2035639041 hasConcept C112705442 @default.
- W2035639041 hasConcept C126322002 @default.
- W2035639041 hasConcept C185592680 @default.
- W2035639041 hasConcept C194409129 @default.
- W2035639041 hasConcept C2778488018 @default.
- W2035639041 hasConcept C2778729363 @default.
- W2035639041 hasConcept C2779282312 @default.
- W2035639041 hasConcept C2779788118 @default.
- W2035639041 hasConcept C2779963572 @default.
- W2035639041 hasConcept C2781121885 @default.
- W2035639041 hasConcept C55493867 @default.
- W2035639041 hasConcept C71924100 @default.
- W2035639041 hasConcept C72563966 @default.
- W2035639041 hasConcept C89560881 @default.
- W2035639041 hasConcept C90924648 @default.
- W2035639041 hasConceptScore W2035639041C104317684 @default.
- W2035639041 hasConceptScore W2035639041C112705442 @default.
- W2035639041 hasConceptScore W2035639041C126322002 @default.
- W2035639041 hasConceptScore W2035639041C185592680 @default.
- W2035639041 hasConceptScore W2035639041C194409129 @default.
- W2035639041 hasConceptScore W2035639041C2778488018 @default.
- W2035639041 hasConceptScore W2035639041C2778729363 @default.
- W2035639041 hasConceptScore W2035639041C2779282312 @default.
- W2035639041 hasConceptScore W2035639041C2779788118 @default.